So apparently Immunovant had a pretty big leadership shuffle last year - Eric Venker came in as the new CEO replacing Pete Salzmann who retired. Venker was already President and COO at Roivant, so it's basically consolidating things under one roof. They brought in Tiago Girao as CFO too.

What caught my attention though is the clinical side of this. They got IND clearance for IMVT-1402 to run what could be a registrational trial for Sjögren's Disease, and they're also running a proof-of-concept study for it in Cutaneous Lupus. That's their fifth and sixth indications for the same drug - pretty ambitious pipeline expansion.

The insider trading data is kind of telling though. Eric Venker himself dumped over 2 million shares for like $22.5M right around this announcement. Institutional investors were mixed on it too - Viking Global cut their position by 11%, but UBS actually increased theirs by over 900%. Morgan Stanley added shares as well, so there's definitely some confidence there despite the leadership change.

Their cash runway supposedly takes them through a Graves' Disease readout in 2027, so they've got runway to execute on this. But with all those new indications, execution is everything. You think Eric Venker's operational background from Roivant will actually help them move faster, or just add more corporate oversight?